CAR-T细胞治疗继发性中枢神经系统弥漫大B细胞淋巴瘤
该单中心回顾性分析纳入7例接受CAR-T治疗的继发性中枢神经系统淋巴瘤成人患者,6例(85.7%)在第28天达完全缓解,中位无进展生存83天,中位总生存129天;5例接受全脑放疗桥接,未增加ICANS风险。
要点
- SCNSL不应因ICANS顾虑而排除CAR-T治疗。
- 全脑放疗桥接未增加ICANS发生率。
- 第28天完全缓解率达85.7%。
核心结论
- 继发性中枢神经系统淋巴瘤不应因ICANS顾虑而排除CAR-T细胞治疗。
- 全脑放疗桥接治疗未增加ICANS风险。
研究设计与样本
- 单中心回顾性分析,纳入7例接受CAR-T治疗的难治性继发性中枢神经系统淋巴瘤成人患者。
主要发现
- 6例(85.7%)在第28天达完全缓解,1例疾病进展。
- 中位无进展生存83天(范围28-219天),中位总生存129天(范围32-219天)。
- 3例因疾病进展死亡。
- 5例接受全脑放疗桥接,其中3例无ICANS,2例发生1级或3级ICANS,无4级ICANS。
关键数值与推荐
- 完全缓解率85.7%(6/7)。
- 中位无进展生存83天(范围28-219天)。
- 中位总生存129天(范围32-219天)。
临床怎么用
- 对继发性中枢神经系统淋巴瘤患者,可考虑CAR-T细胞治疗,不必因ICANS顾虑而排除。
- 全脑放疗作为桥接治疗未增加ICANS风险。
局限性
- 单中心回顾性分析,样本量仅7例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Management of secondary central nervous system (SCNS) involvement in relapsed or refractory aggressive B-cell lymphomas remains an area of unmet medical need. We report a single-center retrospective analysis of 7 adult patients with SCNS lymphoma (SCNSL) who underwent chimeric antigen receptor (CAR) T-cell therapy for their refractory disease, and we describe the safety of whole brain radiation therapy (WBRT) as a bridging therapy. Six patients (85.7%) achieved a complete response at day 28, and 1 patient had progressive disease. The median progression-free survival was 83 days (range, 28-219 days), and median overall survival was 129 days (range, 32-219 days). Three patients died as a result of disease progression. Of the 5 patients who received WBRT as bridging therapy, 3 had no immune effector cell-associated neurotoxicity syndrome (ICANS), but 2 patients had grade 1 or grade 3 ICANS. No grade 4 ICANS was reported in this subset of patients. We conclude that SCNSL should not preclude patients from receiving CAR T-cell therapy as a treatment option because of concerns regarding ICANS, and bridging with WBRT is not associated with increased ICANS.
引用
- Ahmed G, Hamadani M, Shah NN, et al. CAR T-cell therapy for secondary CNS DLBCL. Blood Adv. 2021. PMID: 34551065. doi:10.1182/bloodadvances.2021005292
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。